Tue, 19 May 2026
Hunch
UK drugs29 Aug 2026

UK ketamine seizures hit 1,298kg. Ministers have often overruled drug advisers.

7 months after the drug advisers said ketamine should stay Class B, the Home Office has not answered them. Border Force has seized a record 1,298kg.

4 min read

What happened

Border Force seizures of ketamine reach 1,298kg in the first quarter of 2026, a 42% rise on the previous quarter and the highest quarterly total in 15 years.

The Home Office published the Border Force figures on . The previous record was 1,238kg, in the second quarter of 2025, and 915kg was seized in the last quarter of 2025. Harwich International Port alone accounted for 300kg over the past year, including two loads of 100kg and 200kg from the Hook of Holland.

The release is about enforcement. It warns of lasting bladder damage among young users and says nothing about the drug’s legal class.

The drug advisers said in January that ketamine should stay Class B. The Advisory Council on the Misuse of Drugs (ACMD) wrote to the minister on . It said ketamine and similar drugs should stay below Class A, the strictest group, and the rules for their medical use should not change. The government had asked it in to update its review of harms.

Not everyone agreed. The advice was a majority view in both the Council and its ketamine working group. It came with fourteen further recommendations on supply chains, field testing, treatment and prescribing, and the advisers said no single measure would be enough on its own.

The decision is with ministers. The Misuse of Drugs Act 1971 says the Home Secretary must ask the ACMD before changing a drug’s class, but does not have to follow its advice. It sets no deadline for a reply. If nothing is done, ketamine stays Class B without any decision. That is why the time passed, now seven months, matters more than any fixed date.

Sources: ACMD (2)

The Pattern

We found six cases since 2002 like the ketamine advice. In each, the ACMD advised the Home Secretary against a stricter class for a drug, by asking for no change, a lower class or no control at all, and ministers then decided. We asked whether the Home Secretary chose stricter control than the advisers wanted. Advice asking for stricter control is left out, because there both sides already agree. So are changes to the separate rules for medical use.

4 of 6
Four of the last six times the ACMD advised against tighter control, ministers overruled it: cannabis in 2008, MDMA in 2009, khat in 2013 and nitrous oxide in 2023. The two exceptions, cannabis in 2002 and 2006, were both cases in which the Home Secretary had asked the question and accepted the answer. All four overrides moved in the direction of more control, which is the direction the pressure now points on ketamine. Six cases is the full record since 2002 and the interval around it is wide.
2023 Nitrous oxideheld
The ACMD reported on that nitrous oxide should not be controlled under the Misuse of Drugs Act and that the Psychoactive Substances Act remained the right instrument. The minister replied within the month that the government would control it as a Class C drug, citing anti-social behaviour and reports from frontline policing; the order took effect on . (GOV.UK, Government response to the ACMD nitrous oxide review, March 2023)
2013 Khatheld
The ACMD advised that there was no robust evidence of a causal link between khat and adverse medical effects and did not recommend banning it. The Home Secretary announced on that khat would become a Class C drug, citing community concerns and the risk of the UK becoming a trafficking hub after bans elsewhere in Europe; the order took effect in . (GOV.UK, Khat to be made a Class C drug, 3 Jul 2013)
Show the other 4 cases
2009 MDMAheld
The ACMD’s review published on concluded that the balance of harms of MDMA most closely equated to Class B and recommended reclassification. The Home Office handed the council a letter rejecting the recommendation before the report was published, saying it was not prepared to send a message that it took ecstasy less seriously; MDMA remains Class A. (The Guardian, 11 Feb 2009)
2008 Cannabisheld
Asked again in , the ACMD reported in that a majority of its members considered cannabis should remain Class C. The Home Secretary announced in the intention to reclassify it to Class B, and the order made in 2008 took effect on . (legislation.gov.uk, Explanatory Memorandum to SI 2008/3130)
2006 Cannabisnot held
Asked in to reconsider in the light of evidence on mental health, the ACMD reported in a paper published on that it did not recommend changing the classification of cannabis. No order followed; cannabis stayed in Class C until the 2008 order took effect. (GOV.UK, ACMD, Further consideration of the classification of cannabis, 19 Jan 2006)
2002 Cannabisnot held
Following an ACMD recommendation that cannabis move from Class B to Class C, the Home Secretary told the Commons on that he would seek to reclassify it as a Class C drug by the following July; the order took effect on . (Hansard, HC Deb 10 Jul 2002, Drugs Strategy)

The Read

The most likely outcome is more waiting. Nothing forces a reply, and silence keeps ketamine in Class B without ministers having to defend either choice. So far the Home Office has answered with seizure figures and a health message. The record seizures can be read both ways. They can show the border working, as the release puts it, or show supply growing, which is the argument for Class A. In the past, when a Home Secretary did act on advice like this, it was usually to overrule it.

The advice itself was split. Not all the advisers agreed, which makes it politically cheaper to overrule them. The advisers also accepted that a drug’s class is not the main way to cut how many people use it. A minister could use that point, as one did on nitrous oxide in 2023.

A formal reply that accepts Class B would go against the pattern. It would be only the third time since 2002 that ministers followed advice against stricter control, and the first since 2006.

Disclaimer

Hunch works only from sources that are publicly available, and publishes on the basis of analysis of that material. We do not form an editorial opinion or take sides, we give a simpler and wider view of news that already exists. If information in a source we used was inaccurate, distorted, or later disputed but had already entered our analysis, Hunch accepts no liability for that. Predictions are not advice. Phase 1 markets use Hunch Points, not money.

Published by Hunch under the Editorial Code. Complaints and corrections: /contact/.

Comment

Comments are moderated. Members post under their prediction record.